Paper Details

  1. Home
  2. Paper Details

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.

Author: EnweonyeIgwebuike, FergusonMurdo, HeinemanThomas C, HervéCaroline, LalHimal, MaréchalCéline, OostvogelsLidia, PoderAiri, RheaultPaul, TalliJaak, WautersDominique

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Co-administration of RZV and PPSV23 in adults ≥50 years resulted in no immunologic interference. The vaccine response rate was >98% in both groups and humoral immune responses were non-inferior to sequential administration. The vaccine was safe and well tolerated.
Paper Details　
Original Abstract of the Article :
BACKGROUND: This study evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) when the first dose was co-administered with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults aged ≥50 years. METHODS: In this open label, multi-center study (NCT0204583...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2018.05.110

データ提供：米国国立医学図書館（NLM）

Combining Zoster and Pneumococcal Vaccines: A Double Whammy Against Infections

The [immunization] landscape is constantly evolving, and researchers are exploring novel strategies to enhance vaccine efficacy and convenience. This study investigated the safety and efficacy of administering the [adjuvanted recombinant zoster vaccine (RZV)] alongside the [23-valent pneumococcal polysaccharide vaccine (PPSV23)]. The researchers conducted a [randomized trial] to compare the immunogenicity and safety of co-administration versus sequential administration. They discovered that co-administration of RZV and PPSV23 did not interfere with the immune response to either vaccine, suggesting that this approach is both safe and effective.

Co-administration: A Convenient and Effective Strategy

The study demonstrated that co-administration of RZV and PPSV23 did not diminish the immune response to either vaccine. This finding suggests that co-administration could be a convenient and effective strategy for protecting individuals against both [zoster] and [pneumococcal infections].

Boosting Immunity for a Healthier Life

The ability to combine these two vaccines safely and effectively could streamline the immunization process and improve patient compliance. This could potentially lead to greater protection against serious infections and a healthier population.

Dr.Camel's Conclusion

This research is like a double camel caravan, carrying two powerful vaccines to protect against infections. This efficient strategy is a beacon of hope in the desert of infectious diseases, highlighting the power of collaboration and innovation.

Date :
  1. Date Completed 2018-10-15
  2. Date Revised 2018-10-15
Further Info :

Pubmed ID

29903674

DOI: Digital Object Identifier

10.1016/j.vaccine.2018.05.110

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.